Literature DB >> 12844233

The prognostic value of p53 and DNA ploidy following radical prostatectomy.

C Deliveliotis1, A Skolarikos, A Karayannis, V Tzelepis, N Trakas, E Alargof, V Protogerou.   

Abstract

This study assesses the correlation of p53 immunoreactivity and DNA ploidy status with biochemical recurrence after radical prostatectomy. p53 protein expression and DNA ploidy were evaluated on 84 archival paraffin-embedded radical prostatectomy specimens. Patients were divided into two groups: those with low (38/84, 45%) and those with high (46/84, 55%) p53 immunoreactivity. The results were correlated with Gleason score, stage and serum PSA. Kaplan-Meier biochemical recurrence free survival and the Cox hazard-regression model were used for analysis. Multivariate analysis revealed p53, DNA ploidy, Gleason score, PSA and stage to be independent prognostic factors in this order. Kaplan-Meier analysis showed a significant difference in biochemical recurrence when p53 high expression and DNA aneuploidy were combined. The results of this study suggest that stratification for p53 expression and DNA ploidy status can provide additional prognostic information for patients with prostate carcinoma after radical prostatectomy.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12844233     DOI： 10.1007/s00345-003-0345-0

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


  21 in total

Review 1.  Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999.

Authors:  D G Bostwick; D J Grignon; M E Hammond; M B Amin; M Cohen; D Crawford; M Gospadarowicz; R S Kaplan; D S Miller; R Montironi; T F Pajak; A Pollack; J R Srigley; J W Yarbro
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

2.  The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy.

Authors:  M A Kuczyk; J Serth; C Bokemeyer; S Machtens; A Minssen; W Bathke; J Hartmann; U Jonas
Journal:  Eur J Cancer       Date:  1998-04       Impact factor: 9.162

3.  Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.

Authors:  J J Bauer; I A Sesterhenn; F K Mostofi; D G McLeod; S Srivastava; J W Moul
Journal:  J Urol       Date:  1996-10       Impact factor: 7.450

4.  p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy.

Authors:  J D Oxley; M H Winkler; K Parry; S Brewster; C Abbott; D A Gillatt
Journal:  BJU Int       Date:  2002-01       Impact factor: 5.588

5.  p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.

Authors:  D Theodorescu; S R Broder; J C Boyd; S E Mills; H F Frierson
Journal:  J Urol       Date:  1997-07       Impact factor: 7.450

6.  Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate.

Authors:  T Krupski; G R Petroni; H F Frierson; J U Theodorescu
Journal:  Urology       Date:  2000-05       Impact factor: 2.649

Review 7.  Risk factors for progression in patients with prostate cancer treated with radical prostatectomy.

Authors:  S E Lerner; M L Blute; H Zincke
Journal:  Semin Urol Oncol       Date:  1996-05

8.  An uncertain role for p53 gene alterations in human prostate cancers.

Authors:  J D Brooks; G S Bova; C M Ewing; S Piantadosi; B S Carter; J C Robinson; J I Epstein; W B Isaacs
Journal:  Cancer Res       Date:  1996-08-15       Impact factor: 12.701

9.  Stage B Prostate Cancer: Correlation of DNA Ploidy Analysis With Histological and Clinical Parameters.

Authors: 
Journal:  Cancer Control       Date:  1999-11       Impact factor: 3.302

10.  Influence of DNA ploidy and adjuvant treatment on progression and survival in patients with pathologic stage T3 (PT3) prostate cancer after radical retropubic prostatectomy.

Authors:  C A Hawkins; E J Bergstralh; M M Lieber; H Zincke
Journal:  Urology       Date:  1995-09       Impact factor: 2.649
View more
  6 in total

1.  p53 and cyclooxygenase-2 expression are directly associated with cyclin D1 expression in radical prostatectomy specimens of patients with hormone-naïve prostate cancer.

Authors:  Panagiotis J Vlachostergios; Foteini Karasavvidou; Anna Patrikidou; Ioannis A Voutsadakis; Grigorios Kakkas; George Moutzouris; Elias Zintzaras; Danai D Daliani; Michael D Melekos; Christos N Papandreou
Journal:  Pathol Oncol Res       Date:  2011-07-23       Impact factor: 3.201

2.  DNA ploidy as a prognostic factor in muscle invasive transitional cell carcinoma of the bladder.

Authors:  C Deliveliotis; J Georgoulakis; A Skolarikos; N Trakas; J Varkarakis; S Albanis; B Protogerou; A Bamias
Journal:  Urol Res       Date:  2004-07-17

Review 3.  Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era.

Authors:  Håvard E Danielsen; Manohar Pradhan; Marco Novelli
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

Review 4.  What is the molecular pathology of low-risk prostate cancer?

Authors:  Hemamali Samaratunga; Jonathan I Epstein
Journal:  World J Urol       Date:  2008-04-12       Impact factor: 4.226

Review 5.  [Prostate cancer. Part 1: Review of cell kinetics over the years 1966-2015 and future perspectives of the new grading of the International Society of Urological Pathology (ISUP)].

Authors:  B Helpap; L Bubendorf
Journal:  Pathologe       Date:  2016-02       Impact factor: 1.011

Review 6.  The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review.

Authors:  Naveen Kachroo; Vincent J Gnanapragasam
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-28       Impact factor: 4.553
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.